eFT 508Alternative Names: eFT-508
Latest Information Update: 16 Nov 2016
At a glance
- Originator Effector Therapeutics
- Class Antineoplastics
- Mechanism of Action MKNK1 protein inhibitors; MKNK2 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Cancer; Lymphoma